<DOC>
	<DOCNO>NCT00907452</DOCNO>
	<brief_summary>This protocol ( patient age 65 suffer previously untreated multiple myeloma ) , represent first worldwide , pharmacogenomic study scale term number patient analyze implemented molecular diagnostics resource . The goal able identify patient best respond study treatment experience fewest associate side effect improve prognosis , order optimize care management multiple myeloma . To end , study seek predict follow parameter patient : - The treatment response occurrence adverse event link lenalidomide-dexamethasone combination melphalan-prednisone-thalidomide combination . - Progression-free survival overall survival . Prediction treatment response occurrence adverse effect base : - An analysis constitutive genetic trait link single nucleotide polymorphism DNA copy number variation . - An analysis change tumor 's genotype ( change DNA copy number ) phenotype ( altered gene micro-RNA expression ) . Prediction progression-free survival overall survival base analysis change tumor 's genotype phenotype .</brief_summary>
	<brief_title>Pharmacogenomic Study Myeloma Patients Treated With Melphalan-prednisone-thalidomide Lenalidomide-dexamethasone</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Understand voluntarily sign informed consent form Age ≥ 65 year time sign consent Previously untreated , symptomatic multiple myeloma define 3 criterion : MM diagnostic criterion ( 3 require ) Monoclonal plasma cell bone marrow ≥10 % and/or presence biopsyproven plasmacytoma Monoclonal protein present serum and/or urine Myelomarelated organ dysfunction ( least one follow ) : Calcium elevation blood ( serum calcium &gt; 10.5 mg/l upper limit normal ) Renal insufficiency ( serum creatinine &gt; 2 mg/dl ) Anemia ( hemoglobin &lt; 10 g/dl 2 g &lt; normal ) Lytic bone lesion osteoporosis measurable disease protein electrophoresis analysis define follow : IgG multiple myeloma : Serum monoclonal paraprotein ( Mprotein ) level ≥ 1.0 g/dL urine Mprotein level ≥ 200 mg/24 h IgA multiple myeloma : Serum Mprotein level ³ 0.5 mg/dL urine Mprotein level³ 200 mg/24 h IgM multiple myeloma ( IgM Mprotein plus lytic bone disease document skeletal survey plain film ) : Serum Mprotein level ≥ 1.0 g/dL urine Mprotein level ≥ 200 mg/24h IgD multiple myeloma : Serum Mprotein level ≥ 0.05 g/dL urine Mprotein level ≥ 200 mg/24h Light chain multiple myeloma : Serum Mprotein level ≥ 1.0 g/dL urine Mprotein level ≥ 200 mg/24 hour ECOG performance status 0 , 1 , 2 Treated either melphalanprednisonethalidomide lenalidomide dexamethasone Previous treatment antimyeloma therapy ( include radiotherapy , bisphosphonates , single short course steroid [ i.e. , less equal equivalent dexamethasone 40 mg/day 4 day ; short course steroid treatment must give within 28 day ( 4 week ) randomization ] Any serious medical condition place patient unacceptable risk participates study Any following laboratory abnormality : Absolute neutrophil count ( ANC ) &lt; 1,000 cells/µL ( 1.0 x 109/L ) Platelet count &lt; 50,000 cells/µL ( 50 x 109/L ) patient &lt; 50 % bone marrow nucleate cell plasma cell ; platelet count &lt; 30,000/µL patient ≥ 50 % bone marrow nucleate cell plasma cell Serum SGOT/AST SGPT/ALT &gt; 3.0 x upper limit normal ( ULN ) Creatinine clearance ≤ 30 mL/min ( CockroftGault calculation ) Prior history malignancy , multiple myeloma , unless subject free disease ≥ 3 year . Exceptions include follow : Basal cell carcinoma skin Squamous cell carcinoma skin Carcinoma situ cervix Carcinoma situ breast Incidental histological finding prostate cancer ( TNM stage T1a T1b ) Patients unable unwilling undergo antithrombotic therapy Peripheral neuropathy &gt; grade 2 severity Known HIV positivity active infectious hepatitis , type A , B , C. Primary AL amyloidosis myeloma complicate amyloidosis . Renal failure require dialysis</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Pharmacogenomics</keyword>
	<keyword>prediction response</keyword>
	<keyword>prediction adverse event</keyword>
</DOC>